Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Neurocrine Bio. (NBIX) PT Bumped to $66 at Baird on NBI-98854 Phase 3 Success
October 8, 2015 1:44 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and bumped his price target on Neurocrine Bio. (NASDAQ: NBIX) to $66.00 (from $64.00) saying the Phase 3 success gives them confidence in the outlook.
Skorney commented, "NBI-98854's success in Phase 3 makes the path towards approval... More
Neurocrine Bio. (NBIX) Bullish Stance Reiterated at Cowen
October 8, 2015 12:46 PM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $55 price target on Neurocrine Bio. (NASDAQ: NBIX) after the company announced strongly positive Phase III data for '854 in Tardive Dyskinesia (TD). '854 (80 mg QD) reduced the AIMS score by 3.1 points vs. placebo (p... More
Neurocrine Bio (NBIX) PT Raised to $96 at Piper Jaffray
October 8, 2015 10:52 AM EDTPiper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $96.00 (from $86.00).
Duncan commented, "Today Neurocrine announced positive Phase III results on '854 in Tardive Dyskinesia patients with an underlying psychiatric disorder. Although... More
Pre-Open Stock Movers 10/08: (JMG) (BMR) (EMC) Higher; (CSII) (ORIG) (SHAK) Lower (more...)
October 8, 2015 9:28 AM EDTJournal Media Group, Inc. (NYSE: JMG) 42% HIGHER; Gannett (NYSE:... More
Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive Dyskinesia
October 8, 2015 6:34 AM EDTNeurocrine Biosciences (NASDAQ: NBIX) announced that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying... More
